POTENTIALS FOR THE DRUG CORRECTION OF SECONDARY MITOCHONDRIAL DYSFUNCTION IN PATIENTS WITH CORONARY ARTERY DISEASE AND COMORBID PATHOLOGY


M.E. Statsenko, S.V. Turkina, I.A. Tyshchenko, S.V. Fabritskaya, L.V. Poletaeva

FSBEI HE Volgograd State Medical University of RMH, Volgograd
The article discusses the features of the pathogenesis of mitochondrial dysfunction, which is observed in various pathological conditions accompanied by hypoxia and ischemia. A review of clinical studies and the results of authors’ own experience of use of meldonium as a corrector of secondary mitochondrial dysfunction are presented. Analysis of research confirms that the addition of meldonium to the background therapy is accompanied by a positive clinical effect in cardiovascular and neurological disorders, diabetes mellitus, metabolic syndrome and other diseases with comorbidity.

About the Autors


Corresponding author: M.E. Statsenko – MD, Prof., Head of the Department of Internal Diseases of Pediatric and Stomatological Faculties, Vice Rector for Research FSBEI HE VolSMU of RMH, Volgograd; tel. 8 (8442) 53-23-35; e-mail: mestatsenko@rambler.ru


Similar Articles


Бионика Медиа